These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 505533)

  • 1. Preparation of factor VIII concentrates by cryoprecipitate sedimentation.
    Boudart DJ; Naud MF
    Transfusion; 1979; 19(5):594-6. PubMed ID: 505533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of cryoprecipitated factor VIII concentrates.
    Slichter SJ; Counts RB; Henderson R; Harker LA
    Transfusion; 1976; 16(6):616-26. PubMed ID: 996922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of pooled cryoprecipitate for treatment of hemophilia A in a home care program.
    Smith KJ; Hodges PA
    Transfusion; 1984; 24(6):520-3. PubMed ID: 6438840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of qucik and slow thaw methods of producing cryoprecipitate antihaemophilic factor from fresh and 24-hour-old blood.
    Bloom AL; Giddings JC; Bevan B; Letton M; Drummond RJ
    J Clin Pathol; 1969 Jul; 22(4):447-52. PubMed ID: 5798632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of improved cryoprecipitated factor VIII concentrate. A controlled study of three variables affecting the yield.
    Wensley RT; Snape TJ
    Vox Sang; 1980; 38(4):222-8. PubMed ID: 6774480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified glycine precipitation technique for the preparation of factor VIII concentrate of high purity and high stability.
    Brodniewicz-Proba T; Beauregard D
    Vox Sang; 1987; 52(1-2):10-4. PubMed ID: 3111087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma.
    Vermeer C; Soute BA; Ates G; Brummelhuis HG
    Vox Sang; 1976; 30(1):1-22. PubMed ID: 1251567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severely heated therapeutic factor VIII concentrate of high specific activity.
    Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
    Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
    Teh LC
    Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
    Hughes C; Thomas KB; Schiff P; Herrington RW; Polacsek EE; McGrath KM
    Transfusion; 1988; 28(6):566-70. PubMed ID: 3143170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An improved thaw-siphon method for the cryoprecipitate preparation.
    Kang EP
    Vox Sang; 1980; 38(3):172-7. PubMed ID: 6770544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations in cryoprecipitate production.
    Rock G; Tittley P
    Transfusion; 1977; 17(1):50-3. PubMed ID: 841673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of large-scale plasma thawing for recovery of cryoprecipitate factor VIII.
    Foster PR; Dickson AJ; McQuillan TA; Dickson IH; Keddie S; Watt JG
    Vox Sang; 1982; 42(4):180-9. PubMed ID: 6806984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methods of preparing Factor VIII. I. Preparation and characteristics of a medium-pure concentrate].
    Perote P; Altamirano P; Aperador R; Camacho Y; Acosta J
    Sangre (Barc); 1984; 29(3):321-8. PubMed ID: 6435268
    [No Abstract]   [Full Text] [Related]  

  • 17. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
    Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
    Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
    Branović K; Gebauer B; Trescec A; Benko B
    Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the procurement of coagulation factor VIII: selective precipitation of factor VIII with hydrophilic polymers.
    Farrugia A; Griffin B; Pepper D; Prowse C
    Thromb Haemost; 1984 Jul; 51(3):338-42. PubMed ID: 6437004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.